Fan-Lu Kung
Overview
Explore the profile of Fan-Lu Kung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang H, Kung F, Huang Y, Hsu C, Guh J, Hsu L
Biochem Pharmacol
. 2024 Mar;
223:116140.
PMID: 38513740
Cancer cells consume more glucose and usually overexpress glucose transporters which have become potential targets for the development of anticancer drugs. It has been demonstrated that selective SGLT2 inhibitors, such...
2.
Huang Y, Huang Y, Kung F, Lin C, Jao T, Ho Y
CPT Pharmacometrics Syst Pharmacol
. 2023 Sep;
12(12):1960-1971.
PMID: 37735924
The anticonvulsant valproic acid (VPA) despite complex pharmacokinetics has been in clinical use for nearly 6 decades. Previous reports indicated neonates, infants, and toddlers/preschoolers had higher risk of valproate hepatotoxicity...
3.
Hsu Y, Kung F, Huang T, Deng Y, Guh J, Marchetti P, et al.
Molecules
. 2023 Mar;
28(5).
PMID: 36903603
Hepatocellular carcinoma is the third most common cause of cancer-related death according to the International Agency for Research on Cancer. Dihydroartemisinin (DHA), an antimalarial drug, has been reported to exhibit...
4.
Hung H, Li L, Guh J, Kung F, Hsu L
Molecules
. 2022 Nov;
27(22).
PMID: 36432207
Tumor cells rely on aerobic glycolysis to support growth and survival, thus require more glucose supply. Glucose transporters GLUTs, primarily GLUT1, are overexpressed in various cancers. Targeting GLUTs has been...
5.
Zhang N, Wang T, Chou C, Wu K, Yang C, Kung F, et al.
Eur J Pharmacol
. 2022 Sep;
933:175256.
PMID: 36088983
Many studies have indicated that the risk of cognitive impairment is higher in patients with rheumatoid arthritis (RA). Additionally, patients with RA may have a lower incidence of cognitive impairment...
6.
Weng H, Sung C, Hsu J, Leu W, Guh J, Kung F, et al.
Front Pharmacol
. 2022 Jun;
13:879748.
PMID: 35662690
Breast cancer is the most prevalent cancer and the second leading cause of cancer death in women. Cisplatin is a commonly used chemotherapeutic drug for breast cancer treatment. Owing to...
7.
Ho Y, Hsieh K, Kung F, Wu F, Hsieh L, Chou H, et al.
AJR Am J Roentgenol
. 2015 Sep;
205(4):703-8.
PMID: 26397318
Objective: For unknown reasons, there is discordance among previous reports with regard to the association of contrast medium (CM) with nephropathy and the incidence of nephropathy after contrast-enhanced CT. This...
8.
Hsu J, Liu F, Hsu L, Chang H, Leu W, Yu C, et al.
Oncotarget
. 2015 Jul;
6(27):24032-46.
PMID: 26125228
Epi-reevesioside F, a new cardiac glycoside isolated from the root of Reevesia formosana, displayed potent activity against glioblastoma cells. Epi-reevesioside F was more potent than ouabain with IC50 values of...
9.
Chang P, Talekar R, Kung F, Chern T, Huang C, Ye Q, et al.
Neuropharmacology
. 2015 Jan;
92:146-57.
PMID: 25596491
Alzheimer's disease is a neurodegenerative disorder characterized by deposition of β-amyloid (Aβ) fibrils accompanied with progressive neurite loss. None of the clinically approved anti-Alzheimer's agents target both pathological processes. We...
10.
Liu F, Hsu J, Lee Y, Dong Y, Kung F, Chen C, et al.
Eur J Pharmacol
. 2014 Mar;
730:90-101.
PMID: 24607408
Glioblastoma, a highly malignant glioma, is resistant to both radiation and chemotherapy and is an intractable problem in clinical treatment. New therapeutic approaches are in urgent need. Calanquinone A, an...